Last reviewed · How we verify
Wy21901 (INDORAMIN)
Wy21901 (generic name: INDORAMIN) is a indoramin drug. It is currently FDA-approved.
Wy21901 is a small molecule with the synonyms INDORAMIN HCL, INDORAMIN HYDROCHLORIDE, and WY-21,901 HCL.
At a glance
| Generic name | INDORAMIN |
|---|---|
| Drug class | indoramin |
| Target | D(4) dopamine receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wy21901 CI brief — competitive landscape report
- Wy21901 updates RSS · CI watch RSS
Frequently asked questions about Wy21901
What is Wy21901?
Wy21901 (INDORAMIN) is a indoramin drug.
What is the generic name of Wy21901?
INDORAMIN is the generic (nonproprietary) name of Wy21901.
What drug class is Wy21901 in?
Wy21901 belongs to the indoramin class. See all indoramin drugs at /class/indoramin.
What development phase is Wy21901 in?
Wy21901 is FDA-approved (marketed).
What does Wy21901 target?
Wy21901 targets D(4) dopamine receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor and is a indoramin.
Related
- Drug class: All indoramin drugs
- Target: All drugs targeting D(4) dopamine receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing